Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

46 results about "Ribociclib" patented technology

Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.

Polymorph of ribociclib salt

The present application provides polymorph of Ribociclib citrate salt and pharmaceutical compositions thereof. The present invention also relates to preparation method thereof. In particular, the invention relates to Ribociclib citrate dihydrate.
Owner:ALEMBIC PHARMA

Ribociclib tablet

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
Owner:NOVARTIS PHARM CORP

Zirconium-iron bimetallic nano material, preparation method and application of zirconium-iron bimetallic nano material in preparation of medicine for treating breast cancer

The invention belongs to the technical field of biological medicines, and particularly relates to a ferrozirconium bimetallic nano-material, a preparation method and application of the ferrozirconium bimetallic nano-material in preparation of medicines for treating breast cancer. The ferrozirconium bimetallic nano material is formed by loading a CDK4 / 6 inhibitor on a nano carrier; wherein the nano carrier is an organic framework material Zr-Fe MOF containing double metals of Zr and Fe, and the CDK4 / 6 inhibitor is preferably ribociclib. A product ZFRH for treating breast cancer is obtained based on coupling of the ferrozirconium bimetallic nano-material provided by the invention with a targeted drug such as trastuzumab. The ZFRH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of combined anti-tumor of trastuzumab and a CDK4 / 6 inhibitor. As a safe and effective tumor treatment strategy, the ZFRH has huge clinical transformation potential.
Owner:AIR FORCE MEDICAL CENT PLA

Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation

PCT designated stage expiredWO2025144118A1Organic active ingredientsOrganic chemistryPharmaceutical drugRibociclib
The present invention refers to a crystalline form of Ribociclib dihydrochloride (dihydrate) designated as Form A and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of breast cancer.
Owner:DEVA HLDG

Targeting CDK4 / 6 molecular imaging probe labeling precursor, probe and preparation method and application of targeting CDK4 / 6 molecular imaging probe labeling precursor

The invention relates to the technical field of medicinal chemistry, radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a CDK4 / 6-targeted molecular imaging probe labeling precursor, a probe and a preparation method and application thereof. According to the molecular imaging probe [68Ga] Ga-PY03 provided by the invention, on the basis of a Ribociclib structure, a PEG1 chain and proline with envelope conformation are introduced, so that a hydrophobic region in a protein binding pocket can be filled, Van der Waals force can be enhanced, the molecular imaging probe [68Ga] Ga-PY03 can be stably bound with CDK4 / 6, and the targeting of the molecular imaging probe to the CDK4 / 6 is further ensured; the hydrophilicity of the molecular imaging probe can be adjusted, and kidney uptake is reduced; and the compound has excellent tumor / liver and tumor / muscle ratio, and can effectively improve tumor uptake.
Owner:SHANDONG UNIV

Preparation method of ribociclib intermediate

The invention discloses a ribociclib intermediate preparation method, which comprises: adding a compound (I) into DMSO or DMF, dropwise adding DIEA or triethylamine, and carrying out a ring closing reaction under the action of a catalyst cuprous chloride or cuprous bromide to generate a compound (II); adding the compound (II) into a reaction solvent, controlling the temperature at 70-110 DEG C, adding an oxidant manganese dioxide, carrying out a heat preservation reaction until the raw material disappears, filtering a solid, adding potassium carbonate into a mother solution, controlling the temperature at 0-20 DEG C, dropwise adding hydrogen peroxide, continuously oxidizing until an intermediate disappears, adding water to carry out a quenching reaction, extracting impurities by using an organic solvent, adjusting the pH value of a water phase, separating out the solid, and filtering to obtain a compound (III), one or more of toluene; and finally, the compound (III) generates an intermediate state in a solvent E through a condensing agent CDI or EDCI, after methanol is dropwise added for reaction, water is added for quenching and filtering to obtain a compound (IV), and the solvent E is any one of DMF, tetrahydrofuran and methyl tetrahydrofuran. # imgabs0 #
Owner:TIANJIN PHARMACN MEDICAL TECH

Methods for treating breast cancer

PendingCN121013734AOrganic active ingredientsPeptide/protein ingredientsEndocrine therapyRadiopharmaceutical Compound
The present disclosure relates to methods of treating breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, such as [177Lu] Lu-NeoB, in combination with a CDK4 / 6 inhibitor, such as ribociclib, and a therapeutically effective amount of an endocrine therapy, such as fulvestrant.
Owner:NOVARTIS AG

Methods for treating PSMA-expressing cancers

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.
Owner:ENDOCYTE INC

Ribociclib Tablet

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
Owner:NOVARTIS PHARM CORP

Ribociclib Tablet

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
Owner:NOVARTIS AG

Method of selecting treatment for cancer patient

The present disclosure relates to novel predictive methods and personalized therapies for treating patients with cancer, such as breast cancer. In particular, the present disclosure relates to methods of treating a patient having cancer by selectively administering a combination of a CDK 4 / 6 inhibitor and letrozole. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful for predicting the likelihood that a patient having a cancer, such as breast cancer, will respond to a combination treatment of a CDK 4 / 6 inhibitor, such as ribociclib and an aromatase inhibitor letrozole.
Owner:NOVARTIS AG

Combination therapy of hypoxia-responsive prodrug of an anticancer drug and radiotherapy, and novel hypoxia-responsive prodrug

A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
Owner:UNIV OF TSUKUBA

CDK4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 inhibitor

Disclosed are methods, uses, and combinations for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HIER2−) advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 inhibitor, the methods, uses, and combinations including the administration of a CDK4 and 6 inhibitor in combination with fulvestrant. The methods uses and combinations may include a CDK4 and 6 inhibitor such as palbociclib, ribociclib, or abemaciclib with fulvestrant.
Owner:ELI LILLY & CO

Ribociclib intermediate and synthesis method thereof

The invention provides a ribociclib intermediate compound as well as a preparation method and application thereof, and the intermediate compound V has the following structural formula: # imgabs0 #, in the formula, R1 is alkoxy or dimethylamino; r2 is a C1-C6 alkyl group; and R3 is alkyl with 1 to 12 carbon atoms.
Owner:ZHEJIANG JIUZHOU PHARM CO LTD +1

Ribociclib intermediate and preparation method thereof

The ribociclib intermediate compound and the preparation method thereof have the advantages that raw materials and auxiliary materials are cheap, atom economy is high, the ribociclib intermediate compound is green and safe, substrate universality is high, technological operation is simple, the ribociclib intermediate compound is suitable for industrial production, and the ribociclib intermediate compound has great potential in the field.
Owner:ZHEJIANG JIUZHOU PHARM CO LTD +1

Pharmaceutical compositions of ribociclib

PCT designated stageWO2025219830A1Organic active ingredientsOrganic chemistryPharmaceutical drugRibociclib
Pharmaceutical compositions of ribociclib ora pharmaceutically acceptable salt thereof are disclosed, wherein the compositions are substantially free of nitrosamines. Pharmaceutical products containing said compositions are also disclosed, as well as methods for preparing and storing said pharmaceutical compositions and pharmaceutical products.
Owner:NOVARTIS AG

Pharmaceutical combination comprising TNO155 and ribociclib

The present invention relates to a pharmaceutical combination comprising TNO155 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with CDK4 / 6 inhibition is beneficial in, for example, the treatment of cancers.
Owner:NOVARTIS AG

Preparation method of N-demethylated ribociclib

The invention discloses a preparation method of N-demethylated ribociclib, which comprises the following steps: step 1, adding a solvent A into a compound (1), adding a condensing agent B, stirring to generate an intermediate state, continuously adding methylamine hydrochloride and triethylamine, and continuously carrying out acid amine condensation reaction to generate a compound (2); 2, dropwise adding a metal reagent solution D into a 4-(6-aminopyridine-3-yl) piperazine-1-carboxylic acid tert-butyl ester tetrahydrofuran solution under the protection of nitrogen, carrying out a heat preservation reaction after dropwise adding, adding a compound (2), and carrying out a heating reaction to generate a compound (3); and 3, removing Boc from the compound (3) in a solvent G under an acid E condition, concentrating and recovering the solvent, adjusting the pH value, and filtering to obtain a compound (4). The method has the advantages of cheap and easily available raw materials, simple steps, high yield and low total cost. The ribociclib succinate impurity reference substance prepared by the method is high in purity, can be used as a ribociclib succinate impurity reference substance, and has great significance in impurity research of the ribociclib succinate impurity reference substance. # imgabs0 #
Owner:TIANJIN PHARMACN MEDICAL TECH

Drug-drug salt of ribociclib and non-steroidal anti-inflammatory drug and application thereof

The invention provides a drug-drug salt of ribociclib (English name Ribociclib) and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, a crystal of the drug-drug salt, a preparation method of the crystal, a pharmaceutical composition containing the crystal and application of the pharmaceutical composition. In the drug-drug salt, ribociclib is connected with a non-steroidal anti-inflammatory drug containing a carboxylic acid group through an intermolecular ionic bond. The drug-drug salt obtained by the invention can realize the synergistic interaction of ribociclib and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, improves the anti-tumor activity of ribociclib, can improve the solubility of ribociclib, and improves the physical stability and bioavailability.
Owner:JIANGSU OCEAN UNIV

PET probe based on radioactive metal mark and preparation method and application thereof

ActiveCN121949289ADoes not affect binding activityReduce compensatory target expressionOrganic active ingredientsOrganic chemistryRibociclibTargeted therapy
The invention belongs to the technical field of medicinal chemistry and nuclear medicine, and particularly relates to a PET probe based on radioactive metal labeling and a preparation method and application of the PET probe. Comprising a compound with a result shown in a formula (I). The radioactive probe disclosed by the invention has an obvious target to non-target ratio, can be used as a candidate probe for targeting CDK4 / 6, realizes precise positioning of tumors, and provides visual guidance for subsequent targeted therapy; due to the high specificity of the CDK4 / 6 gene, the CDK4 / 6 gene is expected to be developed into an accompanying diagnosis medicine, a clinical medication scheme is guided by quantitatively analyzing the CDK4 / 6 expression level in tumor tissue, and personalized treatment is achieved; and meanwhile, a new drug screening means and an analysis approach are provided for revealing the drug resistance mechanism of piperisib, ribociclib or abelsib and the like in breast cancer treatment.
Owner:MAJOR BRAIN DISEASES RES CENT OF CAPITAL MEDICAL UNIV (BEIJING INST OF MAJOR BRAIN DISEASES)

Preparation Method and Use of a Ribociclib Intermediate

The present invention relates to a preparation method and use of a ribociclib intermediate, specifically, the compound of formula A6 is prepared by a substitution reaction of the compound of formula A3 and the compound of formula B under the action of an acid-binding agent, selectively followed by a thiolation reaction, selectively followed by a condensation reaction, and then a ring-closing reaction. The compound of formula A6 of the present invention is prepared into ribociclib after an oxidation reaction, a substitution reaction, a deprotection reaction and a salt formation reaction, which is a process route with significant technical advantages, high reaction efficiency and industrial application prospects.
Owner:SUZHOU NOVARTIS PHARMA TECHONOLOGY CO LTD +1

A CDK4 / 6 inhibitor-loaded nano-carrier targeting breast cancer and preparation and application thereof

PendingCN122351194ANanocarriersA lipoprotein
This invention discloses a CDK4 / 6 inhibitor-loaded nanocarrier for targeting breast cancer, its preparation, and its application. Specifically, the nanoformulation of this invention contains: neutral phospholipids, anionic phospholipids, apolipoproteins and / or their mimic peptides, and a CDK4 / 6 inhibitor; wherein the CDK4 / 6 inhibitor is selected from the group consisting of abexicillin, ribociclib, palbociclib, dalcilib, or combinations thereof. The nanoparticles of this invention can efficiently kill breast cancer cells in vivo, inhibit breast cancer cell proliferation, and improve the prognosis of breast cancer.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for inversely differentiating human scalp fibroblasts into dermal papilla-like cells and application

The invention relates to the technical field of biology, and particularly discloses a method for inversely differentiating human scalp fibroblasts into dermal papilla-like cells and application of the method. Ribociclib hydrochloride and vitamin D2 are added for combined induction, so that the human scalp fibroblasts are directly converted into the dermal papilla-like cells; the dermal papilla-like cells have high biomolecular expression similarity with primary human dermal papilla cells, and the problems that proliferation of the dermal papilla-like cells is limited and the hair induction potential of the dermal papilla-like cells is gradually reduced within a long time are solved.
Owner:SUN YAT SEN UNIVERSITY SHENZHEN +1

Preparation method of ribociclib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2, 3-d] pyrimidine-6-methanol

The invention discloses a ribociclib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2, 3-d] pyrimidine-6-methanol preparation method, which comprises: carrying out a coupling reaction on a compound represented by a formula I and a compound represented by a formula II in the presence of a metal copper catalyst, a ligand, alkali and a solvent to obtain a compound represented by a formula III; the invention discloses a ribociclib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2, 3-d] pyrimidine-6-methanol, which is characterized in that a compound shown in the formula III is subjected to cyclization-deprotection reaction under the action of tetrabutylammonium fluoride and a solvent to obtain a compound shown in the formula IV, namely the ribociclib intermediate 2-chloro-7-cyclopentyl-7H-pyrrolo [2, 3-d] pyrimidine-6-methanol, the reaction formula is as follows: # imgabs0 #, in the structures of the formulas I, II and III, X is Br or I, and R1 is a silicon-based protecting group and is selected from one of TMS, TBS and TBDPS. According to the invention, Sonogashira coupling can be realized only by using a small amount of metal copper, the use of a noble metal catalyst palladium is avoided, the low-price and low-unit-consumption compound as shown in the formula II is used as an alkyne reagent, the dosage of the reagent is small, the dosage of tetrabutylammonium fluoride is greatly reduced, and the cost is saved.
Owner:ZHEJIANG UNIV OF TECH

Pharmaceutical compositions of ribociclib

Pharmaceutical compositions of ribociclib or a pharmaceutically acceptable salt thereof are disclosed, wherein the compositions are substantially free of nitrosamines. Pharmaceutical products containing said compositions are also disclosed, as well as methods for preparing and storing said pharmaceutical compositions and pharmaceutical products.
Owner:NOVARTIS AG

A ribociclib intermediate and its preparation method

The present invention relates to a ribociclib intermediate compound and a preparation method thereof, which has the advantages of cheap raw and auxiliary materials, high atom economy, green and safe, high substrate universality, simple process operation, and suitability for industrial production, and has great potential in this field.
Owner:ZHEJIANG JIUZHOU PHARM CO LTD +1

Ribociclib salts and solid state forms thereof

The present disclosure relates to Ribociclib solid state forms, Ribociclib salts including Ribociclib succinate and solid state forms thereof, as well as processes for preparation thereof and pharmaceutical compositions thereof.
Owner:ASSIA CHEM IND

Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4 / 6 inhibitors

ActiveUS12685719B2ToremifeneEverolimus
This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.
Owner:UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION